# Sub-6A Baseline LLM Narratives — Per-Task Output

- **id_strategy**: `library_search`
- **n_tasks**: 14
- **errors**: 0
- **identification accuracy (mean)**: 72.07%
- **top1 strict rate**: 28.57%
- **top3 acceptance rate**: 28.57%
- **driver precision (mean)**: 0.286
- **driver recall (mean)**: 0.053
- **false noise rate (mean)**: 0.143
- **off-pathway mentions (mean)**: 7.07

---

## e2e_enrich_mammalian_RAMP_P_000000106_seed2068278441

- **GT pathway**: `Tyrosine metabolism`
- **predicted top pathway**: `homocysteine metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.50 | **driver_recall**: 0.20 | **false_noise**: 0.50 | **off_pathway**: 12
- **identification**: strategy=`library_search`, id_acc=0.7777777777777778, n_id=8/9
- **claimed drivers**: ['CAFFEINE', 'Fumaric acid']
- **extracted pathways**: ['homocysteine metabolism', 'Purine metabolism', 'homocysteine cycle', 'biopterin pathway', 'pyrimidine biosynthesis', 'TCA cycle', 'methionine cycle', 'xenobiotic metabolism', 'nucleotide biosynthesis', 'dependent signaling', 'folate cycle', 'energy metabolism']
- **off-pathway examples**: ['homocysteine metabolism', 'Purine metabolism', 'homocysteine cycle', 'biopterin pathway', 'pyrimidine biosynthesis', 'TCA cycle', 'methionine cycle', 'xenobiotic metabolism', 'nucleotide biosynthesis', 'dependent signaling', 'folate cycle', 'energy metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006354915` | `VZCYOOQTPOCHFL` | `VZCYOOQTPOCHFL` | Fumaric acid | True |
| `sub6a-gnps-CCMSLIB00005464521` | `VWWQXMAJTJZDQX` | `None` | None | None |
| `sub6a-gnps-MSBNK-mFam-MC21_000305` | `HLKXYZVTANABHZ` | `MWOOGOJBHIARFG` | Vanillin (known structural isomers: 0; isobaric peaks in run: 0) | False |
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | ReSpect:PT210480 Carbamoyl-DL-aspartic acid|N-Carbamoylaspartate|Ureidosuccinic acid|N-(aminocarbonyl)-DL-aspartic acid|N-Carbamyl-DL-aspartic acid|(2S)-2-(carbamoylamino)butanedioic acid | True |
| `sub6a-gnps-MoNA036446` | `RYYVLZVUVIJVGH` | `RYYVLZVUVIJVGH` | CAFFEINE | True |
| `sub6a-gnps-CCMSLIB00010137493` | `FNKQXYHWGSIFBK` | `FNKQXYHWGSIFBK` | Sapropterin (Chimeric precursor selection) | True |
| `sub6a-gnps-CCMSLIB00006356648` | `VZCYOOQTPOCHFL` | `VZCYOOQTPOCHFL` | Fumaric acid | True |
| `sub6a-gnps-CCMSLIB00005883932` | `FFFHZYDWPBMWHY` | `FFFHZYDWPBMWHY` | DL-Homocysteine - 40.0 eV | True |
| `sub6a-gnps-CCMSLIB00010012777` | `RYYVLZVUVIJVGH` | `RYYVLZVUVIJVGH` | Caffeine - 40.0 eV | True |

### LLM Narrative

The six compounds cluster around three inter‑related metabolic modules – **nucleotide (purine + pyrimidine) biosynthesis**, **one‑carbon/methionine‑homocysteine metabolism**, and **tetrahydro‑biopterin (BH₄) pathways** – while a modest aromatic‐compound signal (vanillin) suggests a minor shift in phenylpropanoid/xenobiotic handling.

### 1. Most likely affected pathways  
- **Purine metabolism** – caffeine (a methyl‑xanthine) and fumaric acid (released during the adenylosuccinate‑lyase step of de‑novo purine synthesis) indicate altered purine turnover.  
- **Pyrimidine de‑novo synthesis** – carbamoyl‑DL‑aspartate is the immediate product of aspartate transcarbamoylase, the committed step of this pathway.  
- **One‑carbon/methionine‑homocysteine cycle** – DL‑homocysteine sits at the hub of methionine reclamation, folate‑mediated one‑carbon transfer and trans‑sulfuration.  
- **BH₄ synthesis/regeneration** – sapropterin (synthetic BH₄) signals activation of the biopterin pathway, which fuels aromatic‑amino‑acid hydroxylases and nitric‑oxide synthases.  

### 2. Key drivers in those pathways  
| Metabolite | Pathway driver |
|------------|----------------|
| **Carbamoyl‑DL‑aspartate** | Direct marker of pyrimidine biosynthesis (first committed step). |
| **Caffeine** | Marker of purine metabolism (xanthine‑derived). |
| **Fumaric acid** | Links purine de‑novo and TCA cycle; its accumulation reflects increased flux through both routes. |
| **DL‑Homocysteine** | Central node of one‑carbon/methionine cycle; elevated levels signal altered methylation/trans‑sulfuration. |
| **Sapropterin** | Indicator of BH₄ pathway activation; downstream of GTP‑cyclohydrolase‑I. |
| **Vanillin** (supporting) | May reflect phenylpropanoid or xenobiotic metabolism, but is not a primary driver. |

### 3. Biological significance  
- **Nucleotide anabolism** – heightened carbamoyl‑aspartate and fumarate suggest increased demand for DNA/RNA precursors, consistent with cell proliferation, immune activation or tissue repair.  
- **Methylation & redox** – elevated homocysteine implies perturbed one‑carbon flux, potentially reducing S‑adenosyl‑methionine (SAM) for DNA/RNA methylation and increasing oxidative stress.  
- **Neurovascular homeostasis** – sapropterin (BH₄) is required for dopamine, serotonin and nitric‑oxide synthesis; its modulation can affect neurotransmission and vascular tone.  
- **Epigenetic impact** – fumarate can inhibit α‑ketoglutarate‑dependent dioxygenases (e.g., TET enzymes), influencing DNA‑methylation patterns.  

Collectively, the profile points to a coordinated metabolic re‑programming that couples **nucleotide biosynthesis** with **altered one‑carbon/methylation capacity** and **BH₄‑dependent signaling**, possibly reflecting a proliferative or stress‑responsive state.

### 4. Up‑/down‑stream relationships  

- **Pyrimidine**: carbamoyl‑phosphate (CPS‑II) → **carbamoyl‑aspartate** → dihydro‑orotate → orotate → UMP → DNA/RNA.  
- **Purine**: PRPP → IMP → (adenylosuccinate → AICAR + **fumarate**) → downstream nucleotides (AMP, GMP).  
- **Homocysteine**: methionine → SAM → SAH → **homocysteine** → cystathionine (CBS) → cysteine → glutathione.  
- **BH₄**: GTP → BH₄ (via GTP‑cyclohydrolase‑I) → aromatic‑amino‑acid hydroxylases & NOS; regeneration involves dihydrofolate‑reductase, linking to folate cycle.  
- **Fumarate** also feeds into the TCA (malate → oxaloacetate), bridging nucleotide and energy metabolism.  

Thus, the observed metabolites reflect upstream activation of carbamoyl‑phosphate and PRPP, downstream use of nucleotides and methylation donors, and downstream consequences for methylation, oxidative balance, and neurotransmission.

---

## e2e_enrich_mammalian_RAMP_P_000052705_seed2572336121

- **GT pathway**: `Statin inhibition of cholesterol production`
- **predicted top pathway**: `cGMP signaling`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 11
- **identification**: strategy=`library_search`, id_acc=1.0, n_id=7/7
- **claimed drivers**: []
- **extracted pathways**: ['cGMP signaling', 'indole metabolism', 'receptor pathway', 'Lysine degradation', 'stress pathway', 'lysine catabolism', 'NO signaling', 'host signaling', 'mevalonate pathway', 'lysine metabolism', 'sterol biosynthesis']
- **off-pathway examples**: ['cGMP signaling', 'indole metabolism', 'receptor pathway', 'Lysine degradation', 'stress pathway', 'lysine catabolism', 'NO signaling', 'host signaling', 'mevalonate pathway', 'lysine metabolism', 'sterol biosynthesis']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006578098` | `YYGNTYWPHWGJRM` | `YYGNTYWPHWGJRM` | (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene | True |
| `sub6a-gnps-CCMSLIB00006578103` | `YYGNTYWPHWGJRM` | `YYGNTYWPHWGJRM` | (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene | True |
| `sub6a-gnps-MSBNK-mFam-MC22_000200` | `ZOOGRGPOEVQQDX` | `ZOOGRGPOEVQQDX` | ReSpect:PT202420 Guanosine-3',5'-cyclic monophosphate|cGMP|cyclic GMP|2-amino-9-[(1S,6R,8R,9R)-3,9-dihydroxy-3-oxo-2,4,7-trioxa-3$l^{5}-phosphabicyclo[4.3.0]nonan-8-yl]-3H-purin-6-one | True |
| `sub6a-gnps-CCMSLIB00005884895` | `WHOOUMGHGSPMGR` | `WHOOUMGHGSPMGR` | INDOLE-3-ACETALDEHYDE - 60.0 eV | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO003927` | `AQHHHDLHHXJYJD` | `AQHHHDLHHXJYJD` | Propranolol | True |
| `sub6a-gnps-MSBNK-mFam-MC23_000524` | `OYIFNHCXNCRBQI` | `OYIFNHCXNCRBQI` | 2-Aminoadipic acid; AIF; CE30; MS2Dec | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO003929` | `AQHHHDLHHXJYJD` | `AQHHHDLHHXJYJD` | Propranolol | True |

### LLM Narrative

**Pathway inference**  
The five metabolites point to four distinct biochemical routes that are likely perturbed by the treatment:

| Metabolite (InChIKey) | Primary pathway | Role in the pathway |
|-----------------------|----------------|----------------------|
| **Squalene** (YYGNTYWPHWGJRM) | **Mevalonate / sterol‑biosynthetic pathway** | First committed triterpene precursor to cholesterol, co‑enzyme Q and dolichol. |
| **cGMP** (ZOOGRGPOEVQQDX) | **Nitric‑oxide‑cGMP signaling cascade** | Second messenger downstream of nitric‑oxide (NO) synthases, natriuretic peptides and some hormone receptors. |
| **Indole‑3‑acetaldehyde** (WHOOUMGHGSPMGR) | **Tryptophan → indole → auxin (IAA) pathway** (also mirrors microbial indole metabolism) | Early intermediate that is oxidized to indole‑3‑acetic acid (IAA) or fed into AhR‑activating indole derivatives. |
| **Propranolol** (AQHHHDLHHXJYJD) | **Xenobiotic / adrenergic‑receptor pathway** (β‑blocker) | Directly blocks β‑adrenergic receptors, altering cAMP production and indirectly influencing NO‑cGMP cross‑talk. |
| **2‑Aminoadipic acid** (OYIFNHCXNCRBQI) | **Lysine degradation / mitochondrial oxidative‑stress pathway** | End‑product of the saccharopine → pipecolic‑acid branch; elevated when lysine catabolism or mitochondrial ROS increases. |

**Key drivers**  
- **Squalene** and **cGMP** are the most upstream metabolites that can be “drivers” of downstream metabolic consequences. Squalene accumulation or depletion directly shifts the flux through the mevalonate route, while cGMP elevation reflects heightened NO signaling.  
- **Indole‑3‑acetaldehyde** and **2‑aminoadipic acid** are downstream indicators (or “read‑outs”) of tryptophan and lysine catabolism, respectively. Their altered levels confirm that those routes are active or under stress.  
- **Propranolol** is an external perturber; its presence explains why β‑adrenergic‑linked pathways may be dampened, which can indirectly raise NO‑cGMP activity as a compensatory mechanism.

**Biological significance**  
- **Sterol changes (squalene)** influence membrane composition and the synthesis of cholesterol‑derived hormones and bile acids, impacting cardiovascular and hepatic health.  
- **cGMP elevation** can promote vasodilation, inhibit platelet aggregation, and modulate cardiac remodeling—effects that may be therapeutic or reflect a stress response.  
- **Indole‑3‑acetaldehyde** suggests altered tryptophan→indole flux, which can affect microbial‑host signaling (AhR activation) and, in plants, auxin‑mediated growth.  
- **2‑Aminoadipic acid** accumulation is a recognized marker of oxidative stress and mitochondrial dysfunction, often seen in insulin resistance or neurodegeneration.  

**Up‑stream / downstream relationships**  
- **Squalene** → cholesterol → steroid hormones (up‑stream → downstream).  
- **Propranolol** → β‑adrenergic inhibition → ↓ cAMP, ↑ NO synthase activity → ↑ cGMP (drug → signaling cascade).  
- **cGMP** is downstream of NOS but can feedback to phosphodiesterases; it also intersects with the mevalonate pathway through isoprenoid‑derived modifiers (e.g., geranylgeranylation).  
- **Indole‑3‑acetaldehyde** is an intermediate that precedes **IAA** (auxin) or can be funneled into AhR ligands; it is downstream of tryptophan and upstream of several biologically active indoles.  
- **2‑Aminoadipic acid** is downstream of lysine degradation, which itself is downstream of protein turnover and mitochondrial lysine metabolism.

Taken together, the treatment appears to trigger a coordinated response that (1) modulates sterol biosynthesis, (2) enhances NO‑cGMP signaling (possibly as a vascular compensatory effect), (3) reshapes tryptophan‑indole metabolism, and (4) induces oxidative/mitochondrial stress as reflected by 2‑aminoadipic acid. The presence of propranolol indicates that a pharmacologic β‑blockade is part of the experimental design, which can explain the crosstalk between adrenergic and NO‑cGMP pathways.

---

## e2e_enrich_mammalian_RAMP_P_000053157_seed2543740977

- **GT pathway**: `Selenium micronutrient network`
- **predicted top pathway**: `drug metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 7
- **identification**: strategy=`library_search`, id_acc=0.6, n_id=5/5
- **claimed drivers**: []
- **extracted pathways**: ['drug metabolism', 'Hexosamine biosynthetic pathway', 'each pathway', 'CYP1 pathway', 'GlcNAc signalling', 'insulin signalling', 'hexosamine pathway']
- **off-pathway examples**: ['drug metabolism', 'Hexosamine biosynthetic pathway', 'each pathway', 'CYP1 pathway', 'GlcNAc signalling', 'insulin signalling', 'hexosamine pathway']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00012060180` | `ZIOZYRSDNLNNNJ` | `UFEHYRPBLFGEJW` | 7-hydroxy-1,4a-dimethyl-9-oxo-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid | False |
| `sub6a-gnps-CCMSLIB00013046732` | `WDZVGELJXXEGPV` | `WDZVGELJXXEGPV` | guanabenz | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO002280` | `FZLJPEPAYPUMMR` | `FZLJPEPAYPUMMR` | N-Acetylglucosamine 1-phosphate | True |
| `sub6a-gnps-CCMSLIB00012332249` | `WDZVGELJXXEGPV` | `WDZVGELJXXEGPV` | guanabenz | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO002278` | `FZLJPEPAYPUMMR` | `JRWZLRBJNMZMFE` | Dobutamine | False |

### LLM Narrative

**Pathways that are most likely perturbed**

| Pathway | Typical activity captured by the data |
|---------|----------------------------------------|
| **Xenobiotic/drug metabolism** (Phase‑I cytochrome‑P450 oxidation, Phase‑II conjugation) | Guanabenz and dobutamine appear unchanged – they are markers of exposure to these compounds and of the enzymes that would normally oxidize or conjugate them. |
| **Poly‑cyclic aromatic hydrocarbon (PAH) metabolism** (aryl‑hydrocarbon‑receptor (AhR) → CYP1A1/1B1) | The phenanthrene‑type hydroxy‑carboxylate is a downstream oxidation product of a parent PAH (e.g., phenanthrene). Its presence points to activation of the AhR‑CYP axis. |
| **Hexosamine biosynthetic pathway (HBP)** | N‑Acetylglucosamine‑1‑phosphate is the first dedicated intermediate of HBP; its accumulation signals increased flux from fructose‑6‑phosphate and glutamine toward UDP‑GlcNAc synthesis. |

**Key drivers in each pathway**

* **Phenanthrene derivative** – a primary output of the PAH‑AhR‑CYP1 pathway; its formation depends on CYP1A1/1B1 activity and is the “driver” that links external pollution exposure to downstream AhR‑mediated transcription of detoxifying enzymes.  
* **N‑Acetylglucosamine‑1‑phosphate** – the central node of HBP; upstream it is generated by GFAT (glutamine‑fructose‑6‑phosphate amidotransferase) and downstream it is converted to UDP‑GlcNAc, feeding glycosylation and O‑GlcNAc signalling.  
* **Guanabenz & Dobutamine** – rather than being metabolites produced by the host, they act as *indicators* of the drug‑metabolising machinery; their unchanged levels suggest either direct administration (treatment group) or inefficient clearance, and they will be further processed by the same CYPs that handle the phenanthrene‑type compound.

**Biological significance**

* **PAH exposure** (reflected by the phenanthrene product) can generate oxidative stress, DNA adducts and activate AhR‑driven inflammatory gene programs.  
* **Drug presence** shows that the experimental treatment included adrenergic (dobutamine) and central‑acting α‑2‑agonist (guanabenz) interventions, which themselves can trigger stress‑kinase pathways (e.g., GCN2, PERK) that also up‑regulate HBP flux.  
* **Elevated N‑Acetylglucosamine‑1‑phosphate** indicates heightened O‑GlcNAcylation potential, influencing transcription factor activity, insulin signalling and nutrient‑sensing, thus tying xenobiotic stress to broader metabolic reprogramming.

**Up‑/down‑stream relationships**

* **PAH branch**: parent PAH (up‑stream) → CYP1A1/1B1 oxidation → hydroxy‑phenanthrene‑carboxylate (detected) → conjugation (glutathione or glucuronate) → excretion (down‑stream).  
* **Hexosamine branch**: fructose‑6‑P + glutamine → GFAT → glucosamine‑6‑P → N‑acetyl‑glucosamine‑1‑phosphate (detected) → UDP‑GlcNAc → protein glycosylation/O‑GlcNAcylation (down‑stream).  
* **Drug branch**: administered drug → (optional) CYP oxidation → phase‑II conjugation → water‑soluble metabolites (down‑stream).  

In summary, the data point to simultaneous activation of PAH/AhR‑driven detoxication, drug metabolism, and a stress‑induced up‑regulation of the hexosamine pathway, with the phenanthrene product and N‑acetylglucosamine‑1‑phosphate acting as the principal endogenous drivers of these interconnected networks.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed269957960

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `The clearest pathway`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 9
- **identification**: strategy=`library_search`, id_acc=0.5555555555555556, n_id=7/9
- **claimed drivers**: ["2'-deoxycytidine", 'SARCOSINE']
- **extracted pathways**: ['The clearest pathway', 'pyrimidine metabolism', 'nucleotide biosynthesis', 'Secondary pathway', 'one-carbon metabolism', 'flavonoid metabolism', 'core pathway', 'salvage pathway', 'Altered salvage pathway', 'The one-carbon metabolism', "compound's pathway"]
- **off-pathway examples**: ['The clearest pathway', 'Secondary pathway', 'one-carbon metabolism', 'flavonoid metabolism', 'core pathway', 'salvage pathway', 'Altered salvage pathway', 'The one-carbon metabolism', "compound's pathway"]

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00005883798` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE - 50.0 eV | True |
| `sub6a-gnps-CCMSLIB00000479749` | `DJJCXFVJDGTHFX` | `WXMOHSHAIVZBLE` | 3-(1-{[(3-chlorophenyl)methyl]carbamoyl}piperidin-2-yl)propanoic acid | False |
| `sub6a-gnps-CCMSLIB00010131208` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | 2'-deoxycytidine | True |
| `sub6a-gnps-MoNA023871` | `UCMIRNVEIXFBKS` | `None` | None | None |
| `sub6a-gnps-MoNA033985` | `PGAVKCOVUIYSFO` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00005883801` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE - 60.0 eV | True |
| `sub6a-gnps-CCMSLIB00005883754` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | URIDINE-5-MONOPHOSPHATE - 30.0 eV | True |
| `sub6a-gnps-CCMSLIB00012855498` | `IKIIZLYTISPENI` | `IKIIZLYTISPENI` | ReSpect:PT204150 Baicalin|Baic-7-GlcA|baicalein-7-O-glucuronide|Baicalein 7beta-D-Glucopyranosiduronate|(2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid | True |
| `sub6a-gnps-CCMSLIB00005720324` | `UCMIRNVEIXFBKS` | `FSYKKLYZXJSNPZ` | SARCOSINE | False |

### LLM Narrative

# Metabolomics Pathway Analysis

## 1. Most Affected Metabolic Pathways

The clearest pathway disruption is **pyrimidine metabolism and de novo nucleotide biosynthesis**, evidenced by three interconnected metabolites:

- **UMP (uridine-5-monophosphate)**: Central intermediate in de novo pyrimidine synthesis
- **2'-Deoxycytidine**: Pyrimidine nucleoside entering salvage pathways
- **dCMP (2'-deoxycytidine 5'-monophosphate)**: Direct precursor to dTMP and DNA synthesis

Secondary pathway involvement includes **one-carbon metabolism** (sarcosine, which interconnects with glycine and methyl group transfer) and **flavonoid metabolism/xenobiotic processing** (baicalin).

## 2. Key Driver Metabolites

**Primary drivers**: UMP and dCMP are the most biologically significant—UMP branches to both RNA synthesis and CTP, while dCMP represents the committed step toward DNA synthesis. These two likely represent the core pathway perturbation.

**Secondary drivers**: Elevated 2'-deoxycytidine suggests either increased nucleoside turnover or altered salvage pathway flux. Sarcosine elevation indicates one-carbon unit flux changes, potentially linked to nucleotide methylation reactions.

## 3. Biological Significance

Simultaneous elevation of pyrimidine nucleotides suggests treatment-induced:
- Increased nucleotide demand (cell proliferation, DNA repair)
- Impaired downstream conversion (feedback inhibition or enzyme blockade)
- Altered salvage pathway activity

The one-carbon metabolism change may reflect wider metabolic reprogramming, as glycine and methyl groups are essential for purine/pyrimidine synthesis.

## 4. Upstream/Downstream Relationships

dCMP sits downstream of deoxycytidine and upstream of dTMP→dTDP→dTTP. Elevated dCMP could indicate:
- **Block at dCMP deaminase** (converting dCMP to dUMP)
- **Increased dCMP synthesis** via salvage pathways

The chlorophenyl-piperidine compound's pathway membership remains unclear; it may represent a xenobiotic or novel endogenous metabolite worth further identification.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed2915906702

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `novo biosynthesis`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 4
- **identification**: strategy=`library_search`, id_acc=0.5, n_id=6/8
- **claimed drivers**: ["2'-deoxycytidine", 'SARCOSINE']
- **extracted pathways**: ['novo biosynthesis', 'glycine metabolism', 'Pyrimidine biosynthesis pathway', 'one-carbon metabolism', 'Nucleic acid metabolism', 'urea cycle', 'glutamate signaling', 'TCA cycle', 'pyrimidine biosynthesis']
- **off-pathway examples**: ['novo biosynthesis', 'urea cycle', 'glutamate signaling', 'TCA cycle']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-MSBNK-Eawag-EA282606` | `YQEZLKZALYSWHR` | `YQEZLKZALYSWHR` | Ketamine | True |
| `sub6a-gnps-CCMSLIB00005720324` | `UCMIRNVEIXFBKS` | `FSYKKLYZXJSNPZ` | SARCOSINE | False |
| `sub6a-gnps-CCMSLIB00005883800` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE - 50.0 eV | True |
| `sub6a-gnps-CCMSLIB00006115119` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | ReSpect:PT210480 Carbamoyl-DL-aspartic acid|N-Carbamoylaspartate|Ureidosuccinic acid|N-(aminocarbonyl)-DL-aspartic acid|N-Carbamyl-DL-aspartic acid|(2S)-2-(carbamoylamino)butanedioic acid | True |
| `sub6a-gnps-CCMSLIB00010142385` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | 2'-deoxycytidine | True |
| `sub6a-gnps-MSBNK-mFam-MC22_000058` | `NCMVOABPESMRCP` | `NMPZCCZXCOMSDQ` | CYTIDINE 2',3'-CYCLIC PHOSPHATE | False |
| `sub6a-gnps-MoNA023871` | `UCMIRNVEIXFBKS` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00000479750` | `PGAVKCOVUIYSFO` | `None` | None | None |

### LLM Narrative

## Metabolic Pathway Analysis

### 1. Most Likely Affected Pathways

The metabolites cluster predominantly around **pyrimidine de novo biosynthesis**, with supporting involvement in **one-carbon/glycine metabolism**:

- **Pyrimidine biosynthesis pathway**: Carbamoyl-DL-aspartic acid → dihydroorotate → orotate → UMP → downstream nucleotides
- **Glycine/one-carbon metabolism**: Sarcosine interlinks with folate cycles and methyl group transfer
- **Nucleic acid metabolism**: dCMP, 2'-deoxycytidine, and cytidine cyclic phosphate are all pyrimidine derivatives

### 2. Key Pathway Drivers

**Carbamoyl-DL-aspartic acid** is the most upstream and pivotal intermediate—it's formed by aspartate transcarbamoylase (ATCase) and commits carbamoyl phosphate to pyrimidine synthesis rather than the urea cycle. **dCMP** and **2'-deoxycytidine** are downstream markers of active DNA synthesis/replication. **Sarcosine** connects to one-carbon metabolism, potentially affecting methylation reactions needed for nucleotide synthesis.

### 3. Biological Significance

Altered pyrimidine precursor levels suggest changes in proliferative capacity, DNA repair activity, or nucleotide pool balance. Ketamine (an NMDA antagonist) may modulate glutamate signaling that influences aspartate availability for this pathway. Disrupted pyrimidine homeostasis has implications for cellular replication, brain development, and potentially neuropsychiatric outcomes.

### 4. Upstream/Downstream Relationships

Carbamoyl-aspartate sits upstream of orotate and UMP synthesis; perturbations here cascade through the entire pyrimidine pool. Conversely, **dCMP deaminase** converts dCMP toward dTMP synthesis—elevated dCMP may indicate feedback inhibition at this step. Ketamine exposure may indirectly affect the TCA cycle intermediate pool (aspartate is a precursor), creating bidirectional regulatory effects on pyrimidine biosynthesis.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed4051904823

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `pyrimidine metabolism`
- **top1_strict**: True | **top3_acc**: True | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 4
- **identification**: strategy=`library_search`, id_acc=0.6363636363636364, n_id=9/11
- **claimed drivers**: []
- **extracted pathways**: ['pyrimidine metabolism', 'novo biosynthesis', 'secondary pathway', 'threonine metabolism', 'one-carbon metabolism', 'nucleotide metabolism', 'upstream pathway', 'Altered pyrimidine metabolism', 'salvage pathway', 'nucleotide biosynthesis']
- **off-pathway examples**: ['novo biosynthesis', 'secondary pathway', 'upstream pathway', 'salvage pathway']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-MoNA033986` | `PGAVKCOVUIYSFO` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00005883757` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | URIDINE-5-MONOPHOSPHATE - 30.0 eV | True |
| `sub6a-gnps-CCMSLIB00000425559` | `OENHQHLEOONYIE` | `OAIJSZIZWZSQBC` | Lycopene | False |
| `sub6a-gnps-CCMSLIB00006115119` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | ReSpect:PT210480 Carbamoyl-DL-aspartic acid|N-Carbamoylaspartate|Ureidosuccinic acid|N-(aminocarbonyl)-DL-aspartic acid|N-Carbamyl-DL-aspartic acid|(2S)-2-(carbamoylamino)butanedioic acid | True |
| `sub6a-gnps-CCMSLIB00000577924` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | 2'-deoxycytidine CollisionEnergy:102040 | True |
| `sub6a-gnps-CCMSLIB00005720346` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE | True |
| `sub6a-gnps-CCMSLIB00000479750` | `PGAVKCOVUIYSFO` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00005883756` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | URIDINE-5-MONOPHOSPHATE - 30.0 eV | True |
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | ReSpect:PT210480 Carbamoyl-DL-aspartic acid|N-Carbamoylaspartate|Ureidosuccinic acid|N-(aminocarbonyl)-DL-aspartic acid|N-Carbamyl-DL-aspartic acid|(2S)-2-(carbamoylamino)butanedioic acid | True |
| `sub6a-gnps-CCMSLIB00005720324` | `UCMIRNVEIXFBKS` | `FSYKKLYZXJSNPZ` | SARCOSINE | False |
| `sub6a-gnps-CCMSLIB00005883797` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE - 20.0 eV | True |

### LLM Narrative

## Analysis of Differentially Abundant Metabolites

### 1. Most Likely Affected Pathways

The metabolite cluster strongly implicates **pyrimidine metabolism/de novo biosynthesis** as the primary affected pathway. Carbamoyl-DL-aspartate is a direct intermediate in the early steps of pyrimidine synthesis (from carbamoyl phosphate and aspartate), while UMP represents a central product of this pathway. The presence of 2'-deoxycytidine and its monophosphate confirms downstream pyrimidine processing is also altered.

A secondary pathway implicated is **glycine/serine/threonine metabolism** via sarcosine, which participates in one-carbon metabolism and the glycine cleavage system.

### 2. Key Drivers

- **Carbamoyl-aspartate**: Serves as the committed early intermediate in pyrimidine synthesis; changes here likely initiate downstream effects.
- **UMP**: Central node connecting de novo synthesis to nucleotide metabolism; elevated levels suggest upstream pathway activation or downstream utilization blockade.

### 3. Biological Significance

Altered pyrimidine metabolism impacts DNA/RNA synthesis, cellular proliferation, and nucleotide pool homeostasis. Carbamoyl-aspartate accumulation could indicate enzyme bottlenecks (possibly carbamoyl aspartate transcarbamylase) or regulatory dysregulation. UMP elevation may reflect feedback inhibition failure or salvage pathway engagement. Sarcosine changes connect to methylation capacity and one-carbon unit availability, which coordinate with nucleotide biosynthesis.

### 4. Upstream/Downstream Relationships

Carbamoyl-aspartate → UMP → (downstream) UTP/CTP → nucleic acid synthesis. The parallel presence of deoxycytidine derivatives suggests involvement of ribonucleotide reduction (dCMP from CDP). These pathways intersect through folate-dependent one-carbon metabolism, explaining the sarcosine connection. Lycopene, while potentially relevant to oxidative stress response, appears peripheral to the core nucleotide metabolic cluster.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed1809628705

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `pyrimidine metabolism`
- **top1_strict**: True | **top3_acc**: True | **driver_prec**: 1.00 | **driver_recall**: 0.17 | **false_noise**: 0.00 | **off_pathway**: 4
- **identification**: strategy=`library_search`, id_acc=0.6666666666666666, n_id=10/12
- **claimed drivers**: ['beta-Alanine']
- **extracted pathways**: ['pyrimidine metabolism', 'beta-alanine biosynthesis', 'uracil catabolism', 'energy metabolism', 'direct pathway', 'nucleotide metabolism']
- **off-pathway examples**: ['beta-alanine biosynthesis', 'uracil catabolism', 'energy metabolism', 'direct pathway']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | ReSpect:PT210480 Carbamoyl-DL-aspartic acid|N-Carbamoylaspartate|Ureidosuccinic acid|N-(aminocarbonyl)-DL-aspartic acid|N-Carbamyl-DL-aspartic acid|(2S)-2-(carbamoylamino)butanedioic acid | True |
| `sub6a-gnps-CCMSLIB00005720338` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-MoNA024139` | `PGAVKCOVUIYSFO` | `None` | None | None |
| `sub6a-gnps-MoNA024276` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | Uridine 5'-monophosphate | True |
| `sub6a-gnps-MSBNK-mFam-MC22_000058` | `NCMVOABPESMRCP` | `NMPZCCZXCOMSDQ` | CYTIDINE 2',3'-CYCLIC PHOSPHATE | False |
| `sub6a-gnps-CCMSLIB00012060180` | `ZIOZYRSDNLNNNJ` | `UFEHYRPBLFGEJW` | 7-hydroxy-1,4a-dimethyl-9-oxo-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid | False |
| `sub6a-gnps-CCMSLIB00005883801` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE - 60.0 eV | True |
| `sub6a-gnps-CCMSLIB00005883904` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | 2' DEOXYCYTIDINE - 30.0 eV | True |
| `sub6a-gnps-MoNA023877` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00013023834` | `XZWYZXLIPXDOLR` | `XZWYZXLIPXDOLR` | metformin | True |
| `sub6a-gnps-MoNA023871` | `UCMIRNVEIXFBKS` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00005883906` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | 2' DEOXYCYTIDINE - 30.0 eV | True |

### LLM Narrative

# Metabolomics Pathway Analysis

## 1. Affected Metabolic Pathways

The metabolite cluster strongly points to **pyrimidine metabolism** as the primary affected pathway, with secondary implications for **beta-alanine biosynthesis** and **mitochondrial energetics**.

## 2. Key Pathway Drivers

**N-Carbamoylaspartate** (HLKXYZVTANABHZ) serves as a critical driver—the first committed step in *de novo* pyrimidine synthesis where carbamoyl phosphate condenses with aspartate. The accumulation of this intermediate suggests potential feedback disruption at the aspartate carbamoyltransferase step.

**UMP** and the cytidine/deoxycytidine nucleotides represent downstream products of the pathway, indicating that the block may be *downstream* of carbamoylaspartate (possibly affecting dihydroorotate dehydrogenase or orotate phosphoribosyltransferase activities).

**Beta-alanine** connects to this pathway via **uracil catabolism**—dihydropyrimidine dehydrogenase converts uracil to dihydrouracil, which is further degraded to beta-alanine. This linkage suggests coordinated disruption of both synthesis and degradation arms.

## 3. Biological Significance

Pyrimidine nucleotides are essential for DNA/RNA synthesis, cellular proliferation, and energy metabolism (ATP analogs). Altered de novo synthesis could indicate:
- Changes in proliferative status
- Nucleotide pool imbalance affecting DNA repair
- Potential mitochondrial stress given metformin presence (which modulates AMPK and mitochondrial function)

## 4. Upstream/Downstream Relationships

```
Carbamoyl-Aspartate → Dihydroorotate → Orotate → UMP
                                              ↓
                        Pyrimidine salvage: Cytidine nucleotides
                                                      ↓
                                         Deoxycytidine/dCMP pool
                                                      ↓
                                         Uracil → Beta-alanine
```

Metformin, while not a direct pathway intermediate, may **upstream regulate** these pathways through AMPK-mediated effects on mitochondrial respiration and potentially nucleotide metabolism. The phenanthrene derivative likely represents an unrelated secondary metabolite or experimental artifact.

---

## e2e_enrich_mammalian_RAMP_P_000053306_seed3100819975

- **GT pathway**: `Pyrimidine metabolism`
- **predicted top pathway**: `pyrimidine metabolism`
- **top1_strict**: True | **top3_acc**: True | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 5
- **identification**: strategy=`library_search`, id_acc=0.8571428571428571, n_id=6/7
- **claimed drivers**: []
- **extracted pathways**: ['pyrimidine metabolism', 'novo biosynthesis', 'uracil degradation', 'carnosine biosynthesis', 'coordinated pathway', 'uracil catabolism', 'nucleotide degradation']
- **off-pathway examples**: ['novo biosynthesis', 'uracil degradation', 'carnosine biosynthesis', 'coordinated pathway', 'uracil catabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-MoNA024139` | `PGAVKCOVUIYSFO` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00006120479` | `CKTSBUTUHBMZGZ` | `CKTSBUTUHBMZGZ` | 2'-Deoxycytidine - 40.0 eV | True |
| `sub6a-gnps-MoNA023877` | `UCMIRNVEIXFBKS` | `UCMIRNVEIXFBKS` | beta-Alanine | True |
| `sub6a-gnps-CCMSLIB00003134725` | `DJJCXFVJDGTHFX` | `DJJCXFVJDGTHFX` | ReSpect:PT203720 Uridine-5'-monophosphate|UMP|U 5???-P|Uridylic acid|uridylate|[(2R,3S,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate | True |
| `sub6a-gnps-CCMSLIB00005883801` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE - 60.0 eV | True |
| `sub6a-gnps-CCMSLIB00006115121` | `HLKXYZVTANABHZ` | `HLKXYZVTANABHZ` | ReSpect:PT210480 Carbamoyl-DL-aspartic acid|N-Carbamoylaspartate|Ureidosuccinic acid|N-(aminocarbonyl)-DL-aspartic acid|N-Carbamyl-DL-aspartic acid|(2S)-2-(carbamoylamino)butanedioic acid | True |
| `sub6a-gnps-MoNA024285` | `NCMVOABPESMRCP` | `NCMVOABPESMRCP` | 2'-DEOXYCYTIDINE 5'-MONOPHOSPHATE | True |

### LLM Narrative

## Pathway Analysis

### 1. Affected Metabolic Pathway(s)

The most significantly affected pathway is **pyrimidine metabolism** (specifically de novo biosynthesis). The metabolite pattern is diagnostic:

- **N-Carbamoylaspartate** is the immediate product of aspartate transcarbamoylase—the first committed step of de novo pyrimidine synthesis
- **UMP** represents the first canonical pyrimidine monophosphate in this pathway
- **2'-Deoxycytidine and dCMP** are downstream deoxyribonucleotide products derived from UMP

β-Alanine likely connects secondarily through **uracil degradation** or **carnosine biosynthesis**, linking to the broader pyrimidine pool.

### 2. Key Pathway Drivers

The primary drivers are **N-Carbamoylaspartate** (upstream entry point) and **UMP** (central intermediate). The simultaneous elevation of both early (carbamoyl-aspartate, UMP) and downstream (dCMP) metabolites suggests coordinated pathway activation rather than a single enzymatic block.

### 3. Biological Significance

Increased pyrimidine nucleotide flux indicates heightened **DNA synthesis capacity** or **nucleotide demand**—consistent with cellular proliferation, repair responses, or treatment-induced stress requiring nucleic acid turnover. Alternatively, this could reflect altered regulation of carbamoyl phosphate synthetase II (CPSII), the rate-limiting step that generates the carbamoyl phosphate feeding this pathway.

### 4. Upstream/Downstream Relationships

```
Aspartate + Carbamoyl phosphate
         ↓ ← CPSII (rate-limiting)
Carbamoyl-aspartate → Dihydroorotate → Orotate → OMP → UMP
                                              ↓
                                    UTP/CTP → DNA/RNA synthesis
                                              ↓
                                    Ribonucleotide reductase
                                              ↓
                                    dCMP → dCTP → DNA synthesis
```

β-Alanine may represent increased uracil catabolism, suggesting concurrent **pyrimidine nucleotide degradation** alongside synthesis—an unusual combination unless cells are actively recycling the pyrimidine ring.

---

## e2e_enrich_mammalian_RAMP_P_000025712_seed4052145624

- **GT pathway**: `Sulindac Action Pathway`
- **predicted top pathway**: `C21-steroid metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 4
- **identification**: strategy=`library_search`, id_acc=0.3333333333333333, n_id=12/12
- **claimed drivers**: []
- **extracted pathways**: ['C21-steroid metabolism', 'COX pathway', 'immune signaling', 'lipid signaling']
- **off-pathway examples**: ['C21-steroid metabolism', 'COX pathway', 'immune signaling', 'lipid signaling']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00012060180` | `ZIOZYRSDNLNNNJ` | `UFEHYRPBLFGEJW` | 7-hydroxy-1,4a-dimethyl-9-oxo-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid | False |
| `sub6a-gnps-CCMSLIB00011428388` | `JNUUNUQHXIOFDA` | `SETWPKONPADPDJ` | Eicosanoids_PGJ2_C20H30O4 | False |
| `sub6a-gnps-CCMSLIB00011428462` | `YIBNHAJFJUQSRA` | `KHQNSSJNIXVKMK` | NCGC00169363-02_C20H30O5_2(5H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]-1-hydroxyethyl]- | False |
| `sub6a-gnps-MSBNK-ACES_SU-AS000616` | `ZESRJSPZRDMNHY` | `RCFJDVCRANOZEL` | 17-Hydroxypregn-4-ene-3,20-dione - 40.0 eV | False |
| `sub6a-gnps-CCMSLIB00003135953` | `ZESRJSPZRDMNHY` | `ZESRJSPZRDMNHY` | Spectral Match to 21-Hydroxyprogesterone from NIST14 | True |
| `sub6a-gnps-CCMSLIB00016270605` | `MLKXDPUZXIRXEP` | `MLKXDPUZXIRXEP` | trans-Sulindac [CCS=200.18] | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000565` | `XNRNNGPBEPRNAR` | `UBWZMPMLSDJDSU` | 15(R),19(R)-hydroxy Prostaglandin F2-alpha | False |
| `sub6a-gnps-CCMSLIB00011428290` | `ZIOZYRSDNLNNNJ` | `UFEHYRPBLFGEJW` | 7-hydroxy-1,4a-dimethyl-9-oxo-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid | False |
| `sub6a-gnps-CCMSLIB00006116167` | `MLKXDPUZXIRXEP` | `MLKXDPUZXIRXEP` | Sulindac - 30.0 eV | True |
| `sub6a-gnps-CCMSLIB00012060235` | `QQUFCXFFOZDXLA` | `XEYBRNLFEZDVAW` | Prostaglandin E2 CollisionEnergy:102040 | False |
| `sub6a-gnps-CCMSLIB00013031181` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | DL-METHIONINE | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000566` | `XNRNNGPBEPRNAR` | `UBWZMPMLSDJDSU` | 15(R),19(R)-hydroxy Prostaglandin F2-alpha | False |

### LLM Narrative

## Pathway Analysis

### 1. Most Likely Affected Pathways

The metabolites cluster around two interconnected pathways:

**a) Arachidonic Acid / Eicosanoid Pathway** – The prostaglandins (PGJ2, PGE2, 15(R),19(R)-hydroxy PGF2α) and the cyclopentenone structure clearly derive from this cascade.

**b) Steroidogenesis (Glucocorticoid/Mineralocorticoid branch)** – The presence of 17-hydroxypregn-4-ene-3,20-dione and 21-hydroxyprogesterone indicates altered C21-steroid metabolism, likely at the CYP17 or CYP21 catalytic steps.

### 2. Key Pathway Drivers

| Pathway | Key Drivers |
|---------|-------------|
| Eicosanoid | **PGE2** (central inflammatory mediator), **PGJ2** (anti-inflammatory PPARγ ligand), **15(R),19(R)-hydroxy PGF2α** (inflammation-specific isomer) |
| Steroidogenesis | **21-Hydroxyprogesterone** (upstream of corticosterone), **17-hydroxyprogesterone** (substrate for CYP17A1) |

The presence of **trans-Sulindac** (a NSAID prodrug) suggests possible COX pathway modulation.

### 3. Biological Significance

- **Enhanced inflammation/immune signaling** via elevated eicosanoids
- **Altered stress response** through glucocorticoid intermediates
- **PPARγ activation potential** from PGJ2 accumulation (anti-inflammatory but can indicate oxidative stress)
- Possible impact on vascular tone, fever response, and pain pathways

### 4. Upstream/Downstream Relationships

- **Upstream**: Arachidonic acid release (phospholipase A2) feeds both eicosanoid and possibly steroid pathways
- **Crosstalk**: PGE2 can suppress cortisol synthesis; elevated prostaglandins may signal feedback inhibition
- **Downstream**: 21-hydroxyprogesterone feeds into aldosterone/corticosterone synthesis; the furanone and phenanthrene compounds may represent xenobiotic or novel lipid metabolites

The co-occurrence suggests the treatment may induce inflammatory challenge or alter lipid signaling broadly.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed1549320213

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `energy metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 1.00 | **driver_recall**: 0.12 | **false_noise**: 0.00 | **off_pathway**: 6
- **identification**: strategy=`library_search`, id_acc=0.75, n_id=6/8
- **claimed drivers**: ['metformin', 'Pyruvic acid']
- **extracted pathways**: ['energy metabolism', 'acid metabolism', 'Pyruvate metabolism', 'TCA cycle', 'Trans-sulfuration pathway', 'One-carbon metabolism']
- **off-pathway examples**: ['energy metabolism', 'acid metabolism', 'Pyruvate metabolism', 'TCA cycle', 'Trans-sulfuration pathway', 'One-carbon metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006553841` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00006676843` | `LCTONWCANYUPML` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00010141258` | `XZWYZXLIPXDOLR` | `XZWYZXLIPXDOLR` | metformin | True |
| `sub6a-gnps-CCMSLIB00013576636` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-methionine | True |
| `sub6a-gnps-VF-NPL-QEHF028146` | `KIDHWZJUCRJVML` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00005883641` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | CYSTEINE - 40.0 eV | True |
| `sub6a-gnps-CCMSLIB00013576635` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | L-methionine | True |
| `sub6a-gnps-CCMSLIB00005883645` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | CYSTEINE - 60.0 eV | True |

### LLM Narrative

## Analysis of Differentially Abundant Metabolites

### 1. Affected Metabolic Pathways

The four metabolites point to convergence on **energy metabolism** and **sulfur amino acid metabolism**:

- **Pyruvate metabolism**: Pyruvic acid sits at the crossroads of glycolysis, gluconeogenesis, and TCA cycle activity
- **Trans-sulfuration pathway**: L-methionine and cysteine are sequentially linked via homocysteine in this pathway
- **One-carbon metabolism**: Methionine donates methyl groups via S-adenosylmethionine (SAM) in methylation cycles
- **Gluconeogenesis/hepatic energy regulation**: Metformin inhibits mitochondrial complex I, reducing ATP production and activating AMPK

### 2. Key Drivers

**Metformin** is likely the primary driver if this represents drug treatment, as it directly inhibits oxidative phosphorylation. **Pyruvic acid** elevation may reflect compensatory glycolysis due to impaired mitochondrial function, or altered gluconeogenic flux. Both sulfur amino acids suggest involvement of **glutathione precursor availability** and methylation capacity.

### 3. Biological Significance

These changes collectively indicate altered hepatic energy sensing. Metformin-induced complex I inhibition would reduce NADH oxidation, slowing TCA cycle flux and potentially explaining pyruvate accumulation. Increased cysteine/methionine suggests enhanced trans-sulfuration to support glutathione synthesis—an adaptive antioxidant response to potential oxidative stress from impaired respiration.

### 4. Upstream/Downstream Relationships

Metformin acts **upstream** by affecting mitochondrial oxidative phosphorylation → altered AMP/ATP ratio → AMPK activation. This influences gluconeogenesis (explaining pyruvate shifts) and downstream processes including amino acid metabolism. The methionine → cysteine conversion occurs downstream of folate/one-carbon metabolism and feeds into glutathione synthesis. Pyruvate accumulation is both a consequence of inhibited TCA flux and a substrate for gluconeogenesis, creating bidirectional relationships with metformin targets.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed2917579066

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `Transsulfuration pathway`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.50 | **driver_recall**: 0.12 | **false_noise**: 0.50 | **off_pathway**: 9
- **identification**: strategy=`library_search`, id_acc=0.8571428571428571, n_id=6/7
- **claimed drivers**: ['L-cysteine', 'milrinone']
- **extracted pathways**: ['Transsulfuration pathway', 'Polyamine biosynthesis', 'Central carbon metabolism', 'acid metabolism', 'TCA cycle', 'acid biosynthesis', 'SAH cycle', 'polyamine metabolism', 'energy metabolism', 'one-carbon metabolism']
- **off-pathway examples**: ['Transsulfuration pathway', 'Polyamine biosynthesis', 'Central carbon metabolism', 'acid metabolism', 'TCA cycle', 'acid biosynthesis', 'polyamine metabolism', 'energy metabolism', 'one-carbon metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00012301293` | `PZRHRDRVRGEVNW` | `PZRHRDRVRGEVNW` | milrinone | True |
| `sub6a-gnps-CCMSLIB00013576274` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | methionine (known structural isomers: 0; isobaric peaks in run: 0) | True |
| `sub6a-gnps-CCMSLIB00006553873` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005884067` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | PUTRESCINE - 30.0 eV | True |
| `sub6a-gnps-CCMSLIB00006676837` | `LCTONWCANYUPML` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00013007994` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-cysteine | True |
| `sub6a-gnps-VF-NPL-QEHF028142` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | PUTRESCINE DIHYDROCHLORIDE | True |

### LLM Narrative

## Analysis of Differentially Abundant Metabolites

### 1. Affected Metabolic Pathways

The metabolites point to two interconnected pathways:

- **Transsulfuration pathway**: Methionine → Cysteine connection
- **Polyamine biosynthesis**: Arginine → Ornithine → Putrescine
- **Central carbon metabolism**: Pyruvate as glycolysis-TCA interface

### 2. Key Drivers

**Methionine and L-cysteine** are the most interconnected drivers. Methionine feeds into the transsulfuration pathway, generating cysteine via cystathionine intermediates. This pathway is central because cysteine is required for glutathione synthesis and antioxidant defense.

**Putrescine** represents a separate but related arm of amino acid metabolism, derived from ornithine in polyamine biosynthesis.

**Pyruvate** acts as a metabolic hub connecting glycolysis to the TCA cycle and providing carbon skeletons for amino acid biosynthesis.

**Milrinone** is a phosphodiesterase-3 inhibitor (drug) that elevates cellular cAMP and is not a natural metabolite—this may indicate a pharmacological treatment effect rather than a metabolic dysregulation.

### 3. Biological Significance

Changes in methionine-cysteine homeostasis suggest altered:
- Methylation capacity (via SAM/SAH cycle)
- Oxidative stress response (via glutathione)
- Protein synthesis rates

Putrescine alterations indicate shifts in cellular proliferation and polyamine metabolism. Combined with pyruvate changes, this suggests global alterations in energy and amino acid metabolism.

### 4. Upstream/Downstream Relationships

```
Arginine → Ornithine → Putrescine (polyamines)
      ↓
Methionine → Homocysteine → Cysteine → Glutathione
                  ↓
              Pyruvate (via anaplerosis)
```

The pathways intersect at the level of amino acid biosynthesis and energy metabolism. Changes in methionine could indirectly affect pyruvate through one-carbon metabolism anaplerosis.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed3265338497

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `polyamine metabolism`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 0.00 | **off_pathway**: 5
- **identification**: strategy=`library_search`, id_acc=0.8888888888888888, n_id=9/9
- **claimed drivers**: []
- **extracted pathways**: ['polyamine metabolism', 'energy metabolism', 'Polyamine biosynthesis', 'one-carbon metabolism', 'carbon metabolism', 'transsulfuration pathway', 'TCA cycle', 'Purine metabolism', 'TCA cycle metabolism', 'purine catabolism', 'nitrogen metabolism', 'homocysteine metabolism', 'urea cycle']
- **off-pathway examples**: ['Polyamine biosynthesis', 'transsulfuration pathway', 'TCA cycle', 'purine catabolism', 'urea cycle']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00005884067` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | PUTRESCINE - 30.0 eV | True |
| `sub6a-gnps-MSBNK-Keio_Univ-KO001471` | `UIJIQXGRFSPYQW` | `UYEUUXMDVNYCAM` | Lumazine | False |
| `sub6a-gnps-CCMSLIB00005883640` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | CYSTEINE - 40.0 eV | True |
| `sub6a-gnps-MoNA036248` | `ALYNCZNDIQEVRV` | `ALYNCZNDIQEVRV` | 4-AMINOBENZOIC ACID | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000887` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-CCMSLIB00005883531` | `ALYNCZNDIQEVRV` | `ALYNCZNDIQEVRV` | 4-AMINOBENZOATE - 70.0 eV | True |
| `sub6a-gnps-CCMSLIB00006553841` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005883632` | `LEHOTFFKMJEONL` | `LEHOTFFKMJEONL` | URATE - 50.0 eV | True |
| `sub6a-gnps-CCMSLIB00005884065` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | PUTRESCINE - 30.0 eV | True |

### LLM Narrative

Based on the listed metabolites, the most coherent biological interpretation points to **disrupted polyamine metabolism, altered one-carbon/folate pathways, and potential oxidative stress or energy metabolism shifts**.

**1. Pathways Likely Affected:**
- **Polyamine biosynthesis:** Putrescine is a direct precursor in this pathway.
- **Folate/one-carbon metabolism:** 4-Aminobenzoic acid (PABA) is a component of folate synthesis, and lumazine is linked to riboflavin (vitamin B2) metabolism, which cofactorizes folate-dependent reactions.
- **Amino acid and central carbon metabolism:** Cysteine (transsulfuration pathway) and pyruvic acid (glycolysis/TCA cycle hub) are central nodes.
- **Purine metabolism:** Urate is the final breakdown product of purines.

**2. Key Drivers:**
- **Putrescine** and **cysteine** are likely key drivers given their direct roles in polyamine and glutathione synthesis (critical for oxidative stress defense).
- **Pyruvic acid** acts as a metabolic crossroads, linking glycolysis to amino acid and TCA cycle metabolism.
- **Urate** may reflect upstream purine catabolism or altered antioxidant responses.

**3. Biological Significance:**
Increased putrescine and urate alongside altered cysteine/pyruvate suggest a scenario of **cellular stress or reprogrammed energy/nitrogen metabolism**. Polyamines are involved in cell growth and signaling; their dysregulation can affect proliferation or stress response. Cysteine is essential for glutathione synthesis, so its change may indicate altered redox capacity. The folate/one-carbon link via lumazine and PABA implies disrupted one-carbon transfer reactions, impacting nucleotide synthesis and methylation.

**4. Upstream/Downstream Relationships:**
- **Pyruvic acid** is upstream of many pathways (glycolysis, gluconeogenesis, amino acid synthesis).
- **Cysteine** can be synthesized from pyruvate via the transsulfuration pathway (connected to homocysteine metabolism).
- **Putrescine** is downstream of ornithine (urea cycle) but can be converted to higher polyamines.
- **Urate** is downstream of purine nucleotides; elevated levels may indicate accelerated purine breakdown or oxidative stress.

In summary, the data collectively suggest **cross-talk between polyamine metabolism, oxidative stress response, and one-carbon folate pathways**, likely reflecting a treatment-induced metabolic stress or adaptive shift.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed1221928389

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `methionine cycle`
- **top1_strict**: True | **top3_acc**: True | **driver_prec**: 0.00 | **driver_recall**: 0.00 | **false_noise**: 1.00 | **off_pathway**: 7
- **identification**: strategy=`library_search`, id_acc=0.9166666666666666, n_id=11/12
- **claimed drivers**: ['Dopamine', 'IS_METHIONINE-METHYL-D3']
- **extracted pathways**: ['methionine cycle', 'transsulfuration pathway', 'Methionine metabolism', 'neurotransmitter biosynthesis', 'carbon metabolism', 'Taurine biosynthesis', 'nitrogen metabolism', 'energy metabolism', 'acid biosynthesis']
- **off-pathway examples**: ['transsulfuration pathway', 'neurotransmitter biosynthesis', 'carbon metabolism', 'Taurine biosynthesis', 'nitrogen metabolism', 'energy metabolism', 'acid biosynthesis']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00006581466` | `KBPHJBAIARWVSC` | `KBPHJBAIARWVSC` | Lutein | True |
| `sub6a-gnps-CCMSLIB00005884063` | `VYFYYTLLBUKUHU` | `VYFYYTLLBUKUHU` | Dopamine | True |
| `sub6a-gnps-MoNA033659` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | IS_METHIONINE-METHYL-D3 | True |
| `sub6a-gnps-CCMSLIB00005883641` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | CYSTEINE - 40.0 eV | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000887` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-VF-NPL-QTOF009478` | `GJAWHXHKYYXBSV` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00006553889` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005884060` | `VYFYYTLLBUKUHU` | `VYFYYTLLBUKUHU` | DOPAMINE - 20.0 eV | True |
| `sub6a-gnps-CCMSLIB00005885000` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | Methionine - 60.00 eV | True |
| `sub6a-gnps-VF-NPL-QEHF028147` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | PUTRESCINE DIHYDROCHLORIDE | True |
| `sub6a-gnps-CCMSLIB00006553841` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00005884011` | `GJAWHXHKYYXBSV` | `GJAWHXHKYYXBSV` | PYRIDINE-2,3-DICARBOXYLATE - 30.0 eV | True |

### LLM Narrative

# Metabolomics Pathway Analysis

## 1. Affected Metabolic Pathways

The most significantly affected pathway is the **methionine cycle and transsulfuration pathway**. This network connects multiple metabolites in your dataset:

- Methionine metabolism links to cysteine via the transsulfuration pathway
- S-adenosylmethionine (SAM) connects methionine to polyamine synthesis (putrescine)
- Cysteine is a precursor for glutathione synthesis and taurine production

Additionally, **neurotransmitter biosynthesis** appears affected given dopamine alterations, and **central carbon metabolism** is implicated through pyruvate.

## 2. Key Driver Metabolites

**Cysteine** and **dopamine** are likely the key drivers. Cysteine sits at a metabolic branch point controlling:
- Glutathione synthesis (antioxidant defense)
- Hydrogen sulfide production (signaling)
- Taurine biosynthesis

**Putrescine** indicates increased polyamine flux, while **pyruvate** suggests altered energy/nitrogen metabolism.

**Note:** IS_METHIONINE-METHYL-D3 appears to be an internal standard, not an endogenous metabolite—exclude from biological interpretation.

## 3. Biological Significance

Changes in this network suggest:
- **Altered redox capacity** (cysteine/glutathione balance)
- **Modified methylation status** (methionine cycle perturbation)
- **Neurochemical shifts** (dopamine alterations)
- **Potential oxidative stress response** (polyamine upregulation)

Lutein, being a xanthophyll antioxidant, may represent a parallel antioxidant response to the metabolic changes observed.

## 4. Upstream/Downstream Relationships

The methionine → homocysteine → cysteine → glutathione axis is crucial. Elevated cysteine could indicate:
- Increased transsulfuration flux (downstream)
- Altered methylation demands (upstream affecting SAM and polyamines)

Pyruvate's presence suggests these changes may influence broader energy metabolism, potentially affecting amino acid biosynthesis and neurotransmitter precursor availability. The interconnected nature suggests the treatment may modulate methionine cycle activity, with cascading effects on antioxidant capacity and neurochemistry.

---

## e2e_enrich_mammalian_RAMP_P_000000026_seed2332602456

- **GT pathway**: `Methionine Metabolism`
- **predicted top pathway**: `Probable pathway`
- **top1_strict**: False | **top3_acc**: False | **driver_prec**: 1.00 | **driver_recall**: 0.12 | **false_noise**: 0.00 | **off_pathway**: 12
- **identification**: strategy=`library_search`, id_acc=0.75, n_id=11/12
- **claimed drivers**: ['Tartaric acid', 'Pyruvic acid']
- **extracted pathways**: ['Probable pathway', 'Polyamine biosynthesis', 'glutamine metabolism', 'tyrosine catabolism', 'homogentisate pathway', 'Ascorbate metabolism', 'dicarboxylate shunt', 'TCA cycle', 'AA catabolism', 'tyrosine degradation', 'sulfuration pathway', 'methionine metabolism', 'energy metabolism']
- **off-pathway examples**: ['Probable pathway', 'Polyamine biosynthesis', 'glutamine metabolism', 'tyrosine catabolism', 'homogentisate pathway', 'Ascorbate metabolism', 'dicarboxylate shunt', 'TCA cycle', 'AA catabolism', 'tyrosine degradation', 'sulfuration pathway', 'energy metabolism']

### Per-spectrum identifications

| spectrum_id | GT InChIKey | predicted | name | correct |
|---|---|---|---|:---:|
| `sub6a-gnps-CCMSLIB00013031139` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-cysteine | True |
| `sub6a-gnps-CCMSLIB00005884071` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | PUTRESCINE - 40.0 eV | True |
| `sub6a-gnps-CCMSLIB00006676829` | `LCTONWCANYUPML` | `None` | None | None |
| `sub6a-gnps-CCMSLIB00006112717` | `WHUUTDBJXJRKMK` | `WHUUTDBJXJRKMK` | D-(-)-Glutamic acid - 30.0 eV | True |
| `sub6a-gnps-CCMSLIB00006676047` | `IGMNYECMUMZDDF` | `IGMNYECMUMZDDF` | ReSpect:PT205590 Homogentisic acid|2,5-DHPOP|Homogentisate|Homogentisinic acid|2,5-Dihydroxyphenylacetate|2,5-Dihydroxyphenylacetic acid|Alcapton|2,5-Dihydroxybenzeneacetic acid|2-(2,5-dihydroxyphenyl)acetic acid | True |
| `sub6a-gnps-CCMSLIB00013576274` | `FFEARJCKVFRZRR` | `FFEARJCKVFRZRR` | methionine (known structural isomers: 0; isobaric peaks in run: 0) | True |
| `sub6a-gnps-VF-NPL-QEHF028154` | `KIDHWZJUCRJVML` | `KIDHWZJUCRJVML` | PUTRESCINE DIHYDROCHLORIDE | True |
| `sub6a-gnps-MSBNK-mFam-MC02_000887` | `XUJNEKJLAYXESH` | `XUJNEKJLAYXESH` | L-Cysteine | True |
| `sub6a-gnps-CCMSLIB00006126553` | `SBJKKFFYIZUCET` | `FEWJPZIEWOKRBE` | Tartaric acid | False |
| `sub6a-gnps-CCMSLIB00006553873` | `LCTONWCANYUPML` | `LCTONWCANYUPML` | Pyruvic acid | True |
| `sub6a-gnps-CCMSLIB00006673216` | `IGMNYECMUMZDDF` | `IGMNYECMUMZDDF` | 25Dihydroxy_phenyl_acetic_acid_homogenistic | True |
| `sub6a-gnps-CCMSLIB00006126550` | `SBJKKFFYIZUCET` | `FEWJPZIEWOKRBE` | Tartaric acid | False |

### LLM Narrative

**Pathway inference**

| Metabolite | Probable pathway(s) |
|------------|--------------------|
| L‑cysteine, methionine | Sulfur‑amino‑acid (trans‑sulfuration) pathway → glutathione synthesis, methylation (SAM) |
| Putrescine | Polyamine biosynthesis (arginine → ornithine → putrescine) |
| D‑glutamic acid | Glutamate / glutamine metabolism; links to TCA (α‑ketoglutarate) and neurotransmitter cycling |
| Homogentisic acid | Phenylalanine/tyrosine catabolism (homogentisate pathway) |
| Tartaric acid | Ascorbate metabolism (plant‑like) or minor TCA‑adjacent dicarboxylate shunt |
| Pyruvic acid | Central carbon hub – glycolysis, gluconeogenesis, TCA anaplerosis |

**Key drivers**

1. **Methionine & L‑cysteine** – upstream‑downstream partners of the trans‑sulfuration route. Their coordinated change drives flux toward glutathione and the methyl‑donor SAM pool.  
2. **Putrescine** – directly reflects activity of the polyamine branch; its production depends on arginine/ornithine and on SAM‑derived decarboxylated SAM.  
3. **Pyruvate** – the convergence point of glycolysis and anaplerotic input to the TCA cycle; altered levels affect overall energy and biosynthetic capacity.  

**Biological significance**

- **Redox & detoxification:** Elevated cysteine (and downstream glutathione) signals a response to oxidative or electrophilic stress.  
- **Methylation & proliferation:** Methionine → SAM fuels methyl‑transfer reactions; polyamine rise (putrescine) is often linked to cell‑growth or stress‑recovery programs.  
- **Aromatic‑AA catabolism:** Increased homogentisic acid suggests up‑regulation of phenylalanine/tyrosine degradation, which can influence melanin precursors and quinone‑type metabolites.  
- **Metabolic flexibility:** Glutamate shifts reflect altered nitrogen partitioning and TCA turnover; pyruvate fluctuations indicate remodeled glycolytic–oxidative balance.  

**Up‑/down‑stream relationships**

- **Methionine ⇢ cysteine:** Cysteine is downstream via the trans‑sulfuration pathway (homocysteine → cysteine). A coordinated increase in both implies enhanced forward flux.  
- **SAM ⇢ polyamines:** Decarboxylated SAM provides the propyl‑amine donor for putrescine synthesis, linking methionine metabolism to polyamine production.  
- **Glutamate ↔ TCA:** α‑Ketoglutarate (TCA) ↔ glutamate transamination, placing glutamate changes in direct relation to TCA‑cycle activity and pyruvate anaplerosis.  
- **Homogentisic acid** is downstream of phenylalanine/tyrosine and does not directly feed into the listed amino‑acid or central‑carbon pathways, but its accumulation signals a shift in aromatic‑AA catabolism.  

Collectively, the data point to a treatment‑induced re‑programming of sulfur‑amino‑acid handling, polyamine biosynthesis, and central carbon flux, with downstream consequences for redox buffering, methylation, and energy metabolism.

---
